Drug Discovery@nature.com 13 September 2013

Advertisement Frontiers in Nutrition is sending out a call to all active researchers and internal medicine experts to help us build a dynamic, highly regarded editorial board! We're currently looking for a Specialist Chief Editor for Public Health Nutrition. Find out more about this and how you can apply for our specialist subject sections here TABLE OF CONTENTS 13 September 2013 News Analysis Research Highlights Research & Reviews Careers Advertisement   Reichert Life Sciences Surface Plasmon Resonance Systems - drug discovery instruments for label-free binding analysis in real time. Reichert SPR systems generate precise kinetics (on/off rates) and affinity data for lead optimization in drug discovery. The systems are ultra-sensitive, flexible and cost-effective. Reichert systems cited in peer-reviewed abstracts. ReichertSPR.com Nature Reviews Drug Discovery is on Twitter Advertisement SciBX is pleased to present: SciBX Summit on Innovation in Drug Discovery and Development 2013 October 29-30, 2013 The Colonnade Hotel, Boston, MA, USA  Click here for more information or to register for this conference today!   News Top Patent watch: Eli Lilly wins Alzheimer's antibody patent dispute doi:10.1038/nrd4122 A court in the UK has ruled that one of Janssen's patents that protected the failed Alzheimer's disease therapy bapineuzumab is invalid. Full Text An audience with: Tachi Yamada doi:10.1038/nrd4110 Tachi Yamada, Takeda's Chief Medical & Scientific Officer, discusses changes at Takeda and in the Japanese pharmaceutical industry. Full Text Flurry of deal-making surrounds new autoimmunity target doi:10.1038/nm0913-1078a Drug companies seek to add research programmes on RORγt inhibitors, which can prevent the differentiation of TH17 cells that are implicated as drivers of various autoimmune diseases. Full Text Pipeline for COPD drugs flows with combination candidates doi:10.1038/nm0913-1079 Combination therapies for COPD face a crowded market, but developers say that the products are more convenient for patients and show promise for reducing symptoms. Full Text Analysis Top Post-translational mAbs doi:10.1038/scibx.2013.913 Researchers have developed a platform capable of producing mAbs that target post-translational modifications such as phosphorylation. The technology could open up a host of new targets for cancer and other diseases associated with aberrant modifications. Full Text The epigenetics pipeline doi:10.1038/nrd4091 Epigenetic alterations are found in a number of diseases. This analysis explores the different approaches that are being pursued to exploit the therapeutic potential of epigenetic targets, and provides an overview of the current epigenetics pipeline. Full Text Research Highlights Top HIV: Efficacy through BibNAbs doi:10.1038/nrd4109 Highly potent bispecific broadly neutralizing antibodies (bNAbs) against a broad range of HIV-1 strains show promise for passive immunization against virus. Full Text Cancer: Special delivery service doi:10.1038/nrd4107 Brain-penetrating nanocarriers loaded with dithiazanine iodide, an FDA-approved antihelminthic, could be used for treating glioblastoma multiforme. Full Text G protein-coupled receptors: A double attack on pain doi:10.1038/nrd4105 Ligands targeting a heteromer consisting of the µ-opioid receptor (the target of the analgesic morphine) and a second GPCR could overcome some of the limitations of morphine. Full Text Research & Reviews Top 50 years of hurdles and hope in anxiolytic drug discovery doi:10.1038/nrd4075 This Review analyses the major trends from a database of published preclinical studies on novel anxiolytic agents in the past 50 years, highlighting issues that may have hampered progress and offering recommendations to improve anxiolytic drug discovery. Full Text Disrupting proton dynamics and energy metabolism for novel cancer therapy doi:10.1038/nrc3579 This Review discusses the interplay among metabolism, hypoxia and pH regulation and whether pH-regulatory systems can be targeted for anticancer therapy. Full Text Mitogen-activated protein kinases in innate immunity doi:10.1038/nri3495 This Review summarizes our current understanding of the regulation and function of mitogen-activated protein kinases (MAPKs) in innate immunity, as well as the mechanisms by which pathogens manipulate MAPK activation and the potential of targeting MAPK pathways for the treatment of inflammatory diseases. Full Text Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond doi:10.1038/nrd4099 Sphingosine-1-phosphate (S1P) has a key role in the control of immune cell trafficking and is involved in disorders including cancer and inflammatory diseases. Here, Spiegel and colleagues discuss the ways in which S1P could be therapeutically targeted and highlight recent data from preclinical studies and clinical trials. Full Text Drug Discovery JOBS of the week Postdoctoral Research Fellow In the Areas of Controlled Drug Delivery and Biomaterials University of Manitoba R&D Scientist � Nonclinical Drug Safety (m / f) Boehringer Ingelheim Pharma GmbH & Co. KG Postdoc Fellow� Drug / siRNA delivery nanoparticle�Molecular Biology University of Hawaii at Hilo, The Daniel K. Inouye College of Pharmacy Senior Project Manager Drug Discovery and Development (m / f) Akron Molecules GmbH Research Laboratory Head (m / f) Oncology Drug Discovery / In vivo Boehringer Ingelheim Veterinary Research Center GmbH & Co. KG More Science jobs from Drug Discovery EVENT 2nd Annual Biomarkers in Drug Discovery & Development 09.10.13 Berlin, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.